HK1145141A1 - Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy - Google Patents

Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Info

Publication number
HK1145141A1
HK1145141A1 HK10111653.3A HK10111653A HK1145141A1 HK 1145141 A1 HK1145141 A1 HK 1145141A1 HK 10111653 A HK10111653 A HK 10111653A HK 1145141 A1 HK1145141 A1 HK 1145141A1
Authority
HK
Hong Kong
Prior art keywords
mipo
huntington
inhibitors
disease
treatment
Prior art date
Application number
HK10111653.3A
Other languages
English (en)
Inventor
Haakan Eriksson
Werner Poewe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1145141A1 publication Critical patent/HK1145141A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK10111653.3A 2007-08-23 2010-12-14 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy HK1145141A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95752307P 2007-08-23 2007-08-23
US95752507P 2007-08-23 2007-08-23
PCT/SE2008/050950 WO2009025618A1 (en) 2007-08-23 2008-08-22 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Publications (1)

Publication Number Publication Date
HK1145141A1 true HK1145141A1 (en) 2011-04-08

Family

ID=40378392

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10111653.3A HK1145141A1 (en) 2007-08-23 2010-12-14 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Country Status (26)

Country Link
US (6) US20090054468A1 (zh)
EP (1) EP2200616B1 (zh)
JP (2) JP5247804B2 (zh)
KR (1) KR101588464B1 (zh)
CN (4) CN101873857A (zh)
AU (1) AU2008289653B2 (zh)
BR (1) BRPI0815681A2 (zh)
CA (1) CA2698205C (zh)
CY (1) CY1113714T1 (zh)
DK (1) DK2200616T3 (zh)
EA (1) EA017510B1 (zh)
ES (1) ES2399846T3 (zh)
HK (1) HK1145141A1 (zh)
HR (1) HRP20130139T1 (zh)
IL (2) IL203738A (zh)
ME (1) ME01510B (zh)
MX (1) MX2010001983A (zh)
MY (1) MY155633A (zh)
NZ (1) NZ584135A (zh)
PH (1) PH12014501180A1 (zh)
PL (1) PL2200616T3 (zh)
PT (1) PT2200616E (zh)
RS (1) RS52665B (zh)
SI (1) SI2200616T1 (zh)
WO (1) WO2009025618A1 (zh)
ZA (1) ZA201000848B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
JP5731718B2 (ja) 2011-11-11 2015-06-10 ファイザー・インク ２−チオピリミジノン
WO2013144088A1 (en) * 2012-03-29 2013-10-03 Basf Se N-substituted hetero-bicyclic compounds and derivatives for combating animal pests ii
US9616063B2 (en) 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
MA42035A (fr) 2015-05-05 2018-03-14 Pfizer 2-thiopyrimidinones
BR112019027717A2 (pt) * 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
EA202090266A1 (ru) * 2017-07-17 2020-06-05 Астразенека Аб Ингибиторы mpo для применения в медицине
JP2022552834A (ja) * 2019-10-10 2022-12-20 バイオヘイブン・セラピューティクス・リミテッド ミエロペルオキシダーゼ阻害剤のプロドラッグ
US20230130225A1 (en) * 2020-03-05 2023-04-27 Biohaven Therapeutics Ltd. Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor
US20230192702A1 (en) * 2020-05-06 2023-06-22 Biohaven Therapeutics Ltd. Process for the preparation of verdiperstat
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
WO2024038131A1 (en) 2022-08-18 2024-02-22 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2024120457A1 (zh) * 2022-12-09 2024-06-13 深圳信立泰药业股份有限公司 一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727259B2 (en) * 1997-09-05 2004-04-27 Kyowa Hakko Kogyo Co., Ltd. Remedial agent for neural degeneration
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
MXPA04007299A (es) * 2002-01-28 2004-10-29 Kyowa Hakko Kogyo Kk Metodos de tratamiento de pacientes que sufren de trastornos de movimiento.
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
EP2029603A1 (en) * 2006-06-05 2009-03-04 Astra Zeneca AB Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor
AR066936A1 (es) * 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Also Published As

Publication number Publication date
CN113633641A (zh) 2021-11-12
CY1113714T1 (el) 2016-06-22
US20130059870A1 (en) 2013-03-07
SI2200616T1 (sl) 2013-03-29
HRP20130139T1 (hr) 2013-03-31
EP2200616A1 (en) 2010-06-30
AU2008289653A1 (en) 2009-02-26
EA017510B1 (ru) 2013-01-30
EA201000202A1 (ru) 2010-10-29
CA2698205A1 (en) 2009-02-26
PL2200616T3 (pl) 2013-04-30
JP2013151547A (ja) 2013-08-08
MY155633A (en) 2015-11-13
CN105687199A (zh) 2016-06-22
US20090054468A1 (en) 2009-02-26
RS52665B (en) 2013-06-28
IL240130A0 (en) 2015-09-24
CA2698205C (en) 2016-06-21
PH12014501180A1 (en) 2015-08-24
NZ584135A (en) 2012-04-27
KR101588464B1 (ko) 2016-01-25
EP2200616A4 (en) 2010-08-25
ES2399846T3 (es) 2013-04-03
PT2200616E (pt) 2013-02-27
CN103638029A (zh) 2014-03-19
IL203738A (en) 2015-08-31
JP2010536849A (ja) 2010-12-02
BRPI0815681A2 (pt) 2015-02-18
KR20100055434A (ko) 2010-05-26
AU2008289653B2 (en) 2012-06-28
JP5247804B2 (ja) 2013-07-24
US20140221400A1 (en) 2014-08-07
MX2010001983A (es) 2010-03-10
CN101873857A (zh) 2010-10-27
ME01510B (me) 2014-04-20
US20110207755A1 (en) 2011-08-25
US20200405724A1 (en) 2020-12-31
EP2200616B1 (en) 2012-12-26
WO2009025618A1 (en) 2009-02-26
US10772890B2 (en) 2020-09-15
DK2200616T3 (da) 2013-03-04
ZA201000848B (en) 2012-07-25
US20190099423A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
HK1145141A1 (en) Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy
IL291175A (en) Compositions and methods for treating collagen-mediated diseases
HK1212598A1 (zh) 用於預防口腔疾病的組合物及方法
IL193356A0 (en) Use of rasagiline for the treatment of multiple system atrophy
EP2297341A4 (en) METHOD AND COMPOSITIONS FOR TREATING MORBUS HUNTINGTON
EP2046993A4 (en) RNA INTERFERENCE COMPOSITIONS AND METHOD FOR TREATING MORBUS HUNTINGTON
HK1134679A1 (zh) 用於治療感染的組合物和方法
IL196465A0 (en) Compositions and methods for the treatment of mucositis
HK1139861A1 (zh) 磷酸二酯酶 抑制劑用在治療肢體活動障礙
HK1245679A1 (zh) 用於治療皮膚疾病和病症的方法和組合物
GB0718446D0 (en) Compositions and methods for the treatment of infection
EP2217238A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA
GB0908173D0 (en) Process for facilitating the management of care
EP2069391A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING EYE DRYING
EP2007790A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN
HK1129596A1 (zh) 治療疾病的方法和配方
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
EP2005964A4 (en) MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF
GB0618309D0 (en) Compositions and methods for the treatment of disease
GB0620693D0 (en) Composition and methods for the treatment of degenerative disease
ZA201001779B (en) Compositions and methods for treating collagen-mediated diseases
IL200296A0 (en) Agents for the treatment of multiple sclerosis and methods of using same

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170822